Gadicke Ansbert's Form 4 filing
Werewolf Therapeutics, Inc. (HOWL) · filed Nov 3, 2025
- Accession no.
- 0001231919-25-000404
- Filed
- Nov 3, 2025, 7:07 PM ET
- Trade date
- Oct 30-Nov 3, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $391.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | 10% Owner |
| MPM Asset Management LLCCIK 0001263048 | 10% Owner |
| MPM BioImpact LLCCIK 0001687078 | 10% Owner |
| UBS Oncology Impact Fund L.P.CIK 0001691428 | 10% Owner |
| MPM Oncology Innovations Fund LPCIK 0001719960 | 10% Owner |
| Oncology Impact Fund (Cayman) Management L.P.CIK 0001721036 | 10% Owner |
| MPM Oncology Innovations Fund GP LLCCIK 0001857903 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 30, 2025 | Common Stock | SSaleDisposed | −86,936 | $1.43 | −$124,318.48 | 6,355,717 | Indirect | |
| Oct 31, 2025 | Common Stock | SSaleDisposed | −114,044 | $1.28 | −$145,976.32 | 6,241,673 | Indirect | |
| Nov 3, 2025 | Common Stock | SSaleDisposed | −94,063 | $1.29 | −$121,341.27 | 6,147,610 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.